Fatima SERHAN, Switzerland

World Health Organization Immunization, Vaccines and Biologicals

Presenter of 1 Presentation

STREPTOCOCCUS PNEUMONIAE GLOBAL SEROTYPE DISTRIBUTION FROM THE WORLD HEALTH ORGANIZATION-COORDINATED GLOBAL INVASIVE BACTERIAL VACCINE-PREVENTABLE DISEASES SURVEILLANCE NETWORK, 2010 TO 2018. (ID 1218)

Session Name
Clinical Sciences - Disease Burden in Infants, Children/Youth, and Adults

Author Of 4 Presentations

STREPTOCOCCUS PNEUMONIAE GLOBAL SEROTYPE DISTRIBUTION FROM THE WORLD HEALTH ORGANIZATION-COORDINATED GLOBAL INVASIVE BACTERIAL VACCINE-PREVENTABLE DISEASES SURVEILLANCE NETWORK, 2010 TO 2018. (ID 1218)

Session Name
Clinical Sciences - Disease Burden in Infants, Children/Youth, and Adults

SEROTYPE CHARACTERIZATION OF STREPTOCOCCUS PNEUMONIAE IDENTIFIED IN MENINGITIS CASES IN SEVERAL ASIAN AND EUROPEAN COUNTRIES (ID 896)

Abstract

Background

We examined the serotype distribution patterns of pneumococcal meningitis in the following countries: Ukraine, Belarus, Azerbaijan, Armenia, Georgia and Uzbekistan. The study was performed within the program for Invasive Bacterial Diseases Sentinel Surveillance implemented in the region by WHO Regional Office for Europe.

Methods

Cerebrospinal fluid samples (CSFs) were collected from patients with suspected meningitis at sentinel hospitals within 2007 – 2017. S. pneumoniae serogroups/serotypes in positive CSFs were determined using qPCR and mPCR. Overall, 2980 CSFs from patients aged under 5 years were tested.

Results

173 (5, 8%) CSFs were positive for S. pneumoniae. Pneumococcal serotypes/serogroups were determined in 77,5% (134) of positive CSFs, 22,5% were not-typeable. 27 serotypes/serogroups were identified. Serotypes 6A/B (17,3%), 14 (15,6%), 19F (13%), 23F (5,8%), 18A/B/C (4,6%), were the most prevalent, followed by others with a prevalence of 2% and less (9V/9A, 4, 6C/6D, 24A/B/F,19A, 5, 3, 1, 23A, 20, 2, 13, 31, 8, 7F/7A, 7C/7B/40, 22F/22A, 21, 15B/15C, 12F/12A/12B/44/46, 11A/11D, 16F).

Conclusions

The proportion of vaccine serotypes amounts to 60, 5% for PCV10 and 64,1% for PCV13, suggesting that the introduction of the conjugate vaccine is feasible and justifiable. Ongoing surveillance is needed to monitor the dynamics of serotype distribution following the introduction of PCVs.

Hide

DECLINING TRENDS IN MENINGITIS AMONG CHILDREN LESS THAN FIVE YEARS OF AGE FOLLOWING THE INTRODUCTION OF THE PNEUMOCOCCAL CONJUGATE VACCINES IN WEST AND CENTRAL AFRICA (ID 973)

Abstract

Background

By 2015, pneumococcal conjugate vaccines (PCVs) had been introduced into the infant immunization programmes of most countries in West and Central Africa. We modelled the trends in meningitis cases and deaths among children before and after PCV introduction.

Methods

A total of 36,901 children under 5 years of age with suspected meningitis were enrolled at sentinel hospitals across 10 West and Central African countries between 2010 and 2016 through the Paediatric Bacterial Meningitis (PBM) Surveillance Network . To assess disease and mortality trends before and after PCV introduction, we applied interrupted time-series models and random effects meta-analysis.

Results

Across the sub-regions, there was a decline of 35% (95% CI 2-57%, p=0.04) in annual suspected meningitis cases and 26% (95% CI 3-44%, p=0.03) in laboratory confirmed meningitis in the post vs. pre-PCV period. Likewise, there was a decreased trend in mortality among suspected meningitis cases (33% decline, 95% CI -23-52%, p=0.27) post PCV introduction. There was considerable heterogeneity among countries with the larger and more precise reduction estimates in countries with >2 years post-PCV surveillance.

meningitis_abstract_1.jpg

Conclusions

We observed significant declines in suspected and confirmed pediatric meningitis across the sub-regions following PCV implementation. Continued monitoring, particularly in countries with more recent PCV introduction is needed.

Hide